HEMLIBRA® was studied in the HAVEN 3 clinical trial, in adults and adolescents aged ≥12 years with hemophilia A without factor VIII inhibitors. To learn more about the study design, please visit the Clinical Trials Overview.

HAVEN 3 efficacy results 

Primary endpoint: Significant reduction in treated bleed rate with HEMLIBRA vs no prophylaxis in patients without FVIII inhibitors

As demonstrated in a prospective intra-patient comparison: The first and only treatment to show a significant reduction in treated bleed rate vs prior prophylaxis in patients without FVIII inhibitors 6-13

As observed over at least 24 weeks (HAVEN 3): Sustained protection meant 0 treated bleeds for most patients

Significantly more patients had 0 bleeds with HEMLIBRA vs prior FVIII prophylaxis or no prophylaxis.

ABR=annualized bleed rate; CI=confidence interval; FVIII=factor VIII; IQR=interquartile range.
*ABR was calculated with a negative binomial regression model, accounting for the different follow-up times.

Efficacy in Patients With Inhibitors

Learn about the primary and secondary results for patients with FVIII inhibitors

Adverse Reactions

Adverse reactions from pooled clinical studies with HEMLIBRA

Dosing Calculator 

Help calculate the dosage for your HEMLIBRA patient